Nanobiotix Total Liabilities
Nanobiotix total liabilities. Based on the latest financial reports, Nanobiotix (NBTX) has total liabilities worth $152.24 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Nanobiotix liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Nanobiotix (2011–2025)
Total liabilities of Nanobiotix from 2011 to 2025. This chart illustrates how Nanobiotix's total liabilities have evolved over time, based on quarterly financial data. Explore Nanobiotix long-term investment allocation to see how much of total assets are deployed in long-term investments.
Nanobiotix Competitors by Total Liabilities
The table below lists competitors of Nanobiotix ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nanjing Yunhai Special Metals Co Ltd
SHE:002182
|
China | CN¥8.79 Billion |
|
Guangdong Goworld Co Ltd
SHE:000823
|
China | CN¥2.66 Billion |
|
YGSOFT Inc
SHE:002063
|
China | CN¥658.01 Million |
|
Global Ship Lease Inc
NYSE:GSL
|
USA | $1.04 Billion |
|
Structure Therapeutics Inc. American Depositary Shares
NASDAQ:GPCR
|
USA | $71.01 Million |
|
TGS ASA SP.ADR/1
F:TGC0
|
Germany | €1.95 Billion |
|
Suning Commerce Group Co Ltd
SHE:002024
|
China | CN¥91.43 Billion |
|
Shenzhen Colibri Technologies Co Ltd
SHE:002957
|
China | CN¥2.92 Billion |
Liability Composition Analysis (2011–2025)
This chart breaks down Nanobiotix's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see NBTX asset base.
Liquidity & Leverage Metrics
Nanobiotix Total Liabilities Ratios Explained
Nanobiotix total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.80 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nanobiotix's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nanobiotix (2011–2025)
The table below shows the annual total liabilities of Nanobiotix from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $152.24 Million | +14.36% |
| 2024-12-31 | $133.12 Million | +39.04% |
| 2023-12-31 | $95.74 Million | +10.28% |
| 2022-12-31 | $86.81 Million | +15.78% |
| 2021-12-31 | $74.98 Million | +17.96% |
| 2020-12-31 | $63.56 Million | +9.37% |
| 2019-12-31 | $58.11 Million | +81.88% |
| 2018-12-31 | $31.95 Million | +135.90% |
| 2017-12-31 | $13.54 Million | +4.15% |
| 2016-12-31 | $13.00 Million | +20.33% |
| 2015-12-31 | $10.81 Million | +60.38% |
| 2014-12-31 | $6.74 Million | +58.29% |
| 2013-12-31 | $4.26 Million | +27.93% |
| 2012-12-31 | $3.33 Million | +67.40% |
| 2011-12-31 | $1.99 Million | -- |
About Nanobiotix
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small … Read more